Nevirapine in the treatment of HIV

References

• Merluzzi V, Hargrave K, Labadia M, et al. Inhibitor of HIV-1 replication by non-nucleoside reverse transcriptase inhibitors. Science 250, 1411–1413 (1990).
   Google Scholar
• ••First description of the in vitro antiretroviral effect of nevirapine, showing specificity for HIV-1 and a high therapeutic index.
   Google Scholar
• Rodgers D, Gamblin S, Hans B, et al. The structure of uniligand reverse transcriptase from the HIV Type 1. Proc. Nad Acad. Sci. USA 92,1222–1230 (1995).
   PubMed Web of Science ®Google Scholar
• Tantillo C, Ding J, Jacobo-Molina A, et al Locations of anti-AIDS drug binding sites and resistance mutations in the three dimensional structure of HIV-1 reverse transcriptase: implications for mechanism of drug inhibition and resistance. J. Mal Biol. 243,396–375 (1994).
   Web of Science ®Google Scholar
• Veldkamp Al, Harris M, Montaner JS, et al. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus Type 1-infected persons. J. Infect. Dis. 185(2), 268–269 (2002).
   Google Scholar
• ••Study showing the pharmacokineticinteraction between nevirapine and efavirenz. Nevirapine plasma concentration was unaffected by efavirenz but efavirenz pharmacokinetic parameters decreased by 20 to 30%, an effect that may be clinically significant.
   Google Scholar
• Van Leth F, Hassink E, Phanuphak P, et al. Results of 2NN study: a randomised comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and Lamivudine. 10th Conference on Retroviruses and Opportunistic Infections (2002) (Abstract 176).
   Google Scholar
• ••First clinical trial comparing nevirapine andefavirenz within triple combination regimens. Nevirapine either twice daily or four-times daily was as effective as efavirenz given four-times daily. Coadministration of nevirapine plus efavirenz resulted in a virological response worse than that of each individual non-nucleoside.
   Google Scholar
• Havlir D, Cheeseman S, McLaughlin M, et al High-dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with HIV infection. J. Infect. Dis. 171,537–545 (1995).
   PubMed Web of Science ®Google Scholar
• Hattox S, Cohn D, Norris, et al Single and multiple dose pharmacokinetics of nevirapine, a novel non-nucleoside HIV-1 reverse transcriptase inhibitor. Pharm. Res. 9, 268–277 (1992).
   Google Scholar
• Taylor S, Hoetelmans R, Workman J, et al Concentrations of nevirapine, lamivudine and stadivudine in the semen of an HIV-infected man. AIDS 14,1979–1984 (2000).
   PubMed Web of Science ®Google Scholar
• Shetty A, Coovadia H, Maldonado, et al Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J. Acquir. Immune Defic. Syndr. 34,482–490 (2003).
   PubMed Web of Science ®Google Scholar
• Sahai J, Cameron W, Salgo M, et al Drug interaction study between saquinavir (SQV) and nevirapine (NVP). 4th Conference on Retroviruses and Opportunistic Infections (1997) (Abstract 496).
   Google Scholar
• Back D, Gibbons S, Khoo S. Pharmacokinetic drug interactions with nevirapine. J. Acquir Immune Defic. Syndr 34, S8—S14 (2003).
   Web of Science ®Google Scholar
• •Good review on pharmacokinetic interactions with nevirapine.
   Google Scholar
• Murphy RL, Sommadossi JP, Lamson M, et al Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus Type 1. J. Infect. Dis. 179,1116–1123 (1999).
   PubMed Web of Science ®Google Scholar
• Benson CA, Deeks SG, Brun SC, et al Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and two nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus Type 1-infected protease inhibitor-experienced patients. J. Infect. Dis. 185,599–607 (2002).
   PubMed Web of Science ®Google Scholar
• •Shows the efficacy of nevirapine in non-nucleoside reverse transcriptase inhibitor (NNRTI)-naive, protease inhibitor (PI)-experienced patients when administered together with lopinavir/ritonavir.
   Google Scholar
• Hsu A, Bertz R, Reiz C, et al. Assessment of pharmacokinetic interactions between kaletra (lopinavir/ritonavir or ABT-378/r) and nevirapine in pediatric subjects. AIDS 14\(Suppl. 4), S100 (2000).
   Google Scholar
• Clark SM, Mulcahy F, Tjia J, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat drug injection users. Clin. Infect. Dis. 33, 1595–1597 (2001).
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogs by human liver cytochromes P450 III A4. J. Med. Chem. 34,1838–1844 (1991).
   PubMed Web of Science ®Google Scholar
• Robinson P, Lamson M, Gigliotti M. Pharmacokinetic interaction between nevirapine and rifampicin. 39th International Conference Antimicrob. Agents Chemother. (1999) (Abstract 60623).
   Google Scholar
• Robinson P, Gig,liotti M, Lamson M, et al. Effect of the reverse transcriptase inhibitor, nevirapine, on steady-state pharmacokinetics of darithromycin in HIV positive patients. 6th Conference on Retroviruses and Opportunistic Infections (1999) (Abstract 374).
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals INC. Viramune® (nevirapine) Prescribing Information (2002).
   Google Scholar
• Pollard R. Factors predictive of durable HIV suppression in randomised double-blind trial nevirapine (NVP) zidovudine (ZDV) and lamivudine (3TC) in treatment naive (ARV-n) patients with advanced AIDS. 7th Conference on Retroviruses and Opportunistic Infections (2000) (Abstract 517).
   Google Scholar
• Floridia M, Buccardini R, Ricciardulli D, et al. A randomised double-blind trial on the use of a triple combination including nevirapine, a non-nucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advance disease. J. Acquir. Immune Defic. Syndr. 20, 11–19 (1999).
   Web of Science ®Google Scholar
• Podzamcer D, Ferrer E, Consiglio E, et al A randomised clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antiviral Then 7,81–90 (2002).
   PubMed Web of Science ®Google Scholar
• Raffi F, Reliquet V, Ferre V, et al. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1 infected adults. Antiviral Them 267–272 (2003).
   Google Scholar
• Nunez M, Rodriguez-Rosado R, Soriano V, et al. The SENEC Trial: Spanish Efavirenz vs. Nevirapine Comparison Trial. Preliminary results of a prospective, randomised, controlled, open-label study in HIV+ naive individuals. 40th Interscience Conference Antimicrob. Agents Chemother. Toronto, Canada, 17–21 September 2000.
   Google Scholar
• Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir and lamivudine among patients with advanced human immunodeficiency virus disease who had previously failed combination nucleoside therapy. J. Infect. Dis. 177, 1514–1520 (1998).
   Google Scholar
• Deeks S, Hellman NS, Grant RI\4, et al. Novel four-drug salvage treatment regimens after failure of human immunodeficiency virus Type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virological outcome. J. Infect. Dis. 179, 1375–1381 (1999).
   PubMed Web of Science ®Google Scholar
• Lawrence J, Shapiro J, Winters M, et al. Clinical resistance patterns and response to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. J. Infect. Dis. 179,1356–1364 (1999).
   PubMed Web of Science ®Google Scholar
• Montaner J, Harris M, Harrigan R, Hogg R, et al A compromise strategy for patients with multiple drug failure. AIDS 15,2470 (2001).
   PubMed Web of Science ®Google Scholar
• Cotton G. Sustained virological suppression in subjects switched from protease inhibitors to nevirapine. X/// International AIDS Conference (2000) (Abstract WePeB4198).
   Google Scholar
• Barreiro P, Soriano V, Blanco F, et al. Risk and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 14,807–812 (2000).
   PubMed Web of Science ®Google Scholar
• Ruiz L, Negredo E, Domingo P, et al Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. J. Acquir Immune Defic. Syndr. 27,229–236 (2001).
   PubMed Web of Science ®Google Scholar
• Martinez E, Conget I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13,805–810 (1999).
   PubMed Web of Science ®Google Scholar
• •First study showing similar antiretroviral efficacy but less metabolic abnormalities when protease inhibitors are replaced with nevirapine in patients on PI-containing highly-active antiretroviral therapy (HAART) with virological suppression and metabolic abnormalities.
   Google Scholar
• Clotet B, Van der Valk M, Negredo E, Reiss P Impact of nevirapine on lipid metabolism. J. Acquir. Immune Defic. Syndr. 34, S79—S84 (2003).
   Web of Science ®Google Scholar
• Martinez E, Arnaiz JA, Podzamcer D, et al. Substitution of nevirapine, efavirenz or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J. Med. 349(11), 1036–1046 (2003).
   PubMed Web of Science ®Google Scholar
• ••Head-to-head comparison of nevirapine,efavirenz and abacavir as substitutes for protease inhibitors in PI-containing HAART with sustained virological suppression. 2NN was the first comparative study of nevirapine.
   Google Scholar
• Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362(9387), 842–843 (2003).
   PubMed Web of Science ®Google Scholar
• ••Study demonstrating the efficacy of single-dose nevirapine for preventing mother-to-child transmission in resource-limited settings.
   Google Scholar
• Striger J, Rouse D, Vermund S, et al. Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa. J. Acquir. Immune Defic. Syndr. 24, 369–377 (2000).
   PubMed Web of Science ®Google Scholar
• Jackson J, Becker-Pergola G, Guay L, et al. Identification of the K103N resistance mutation in Uganda women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 14,111–115 (2000).
   Web of Science ®Google Scholar
• •Highlights the risk for the development of nevirapine resistance after single dose nevirapine for preventing mother-to-child transmission.
   Google Scholar
• Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus Type 1 transmission (HIV Network for Prevention Trials 012 Study). J. Infect. Dis. 184,914–917 (2001).
   PubMedGoogle Scholar
• Briones C, Soriano V, Dona C, et al. Can early failure with nevirapine be rescued with efvirenz?J. Acquir. Immune Defic. Syndr. 24, 76–78 (2000).
   PubMed Web of Science ®Google Scholar
• Huang W, Parkin N, Lie Y, et al A novel HIV-1 RT mutation (N230L) confers NNRTI resistance and dose-dependent stimulation of replication. Antivir Ther 5\(Suppl. 3), 24–25 (2000).
   Google Scholar
• Whitcomb J, Huang W Limoli K, et al Hypersusceptibility to a non-nucleoside reverse transcriptase inhibitors in HIV-1, clinical, phenotypic and genotypic correlates. AIDS 16,41–47 (2002).
   PubMed Web of Science ®Google Scholar
• Casado J, Hertogs K, Moreno A, et al Factors influencing decreased susceptibility to nevirapine in NNRTI-naive patients. Antiviral Them 5\(Suppl. 3), 25–26 (2000).
   Google Scholar
• Pollard RB, Robinson P, Dransfield K Safety profile of nevirapine, a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin. Ther 20,1071–1092 (1998).
   PubMed Web of Science ®Google Scholar
• Murphy RE. Defining toxicity profile of nevirapine and other antiviral drugs. J. Acquir Immune Defic. Syndr. 34\(Suppl. 1), 15–20 (2003).
   Google Scholar
• Knobel H, Miro JM, Domingo P, et al. Failure of short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J. Acquir Immune Defic. Syndr. 28,14–18 (2001).
   PubMed Web of Science ®Google Scholar
• Montaner J, Gig,liotti M, Cahn P, et al. The effects of short course of prednisone on the incidence of rash associated with nevirapine. XIII International AIDS Confirence, Durban, South Africa, 9-14th July 2000.
   Google Scholar
• Martinez E, Blanco JL, Arnaiz JA, et al Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15, 1261–1268 (2001).
   PubMed Web of Science ®Google Scholar
• Dietrich D, Stern J, Robinson, et al Analyses of four key clinical trials to asses the risk of hepatotoxicity with nevirapine: correlation with CD4+ levels, hepatitis B and C seropositivity and baseline liver function tests. 1st IAS Confirence on HIV Pathogenesis and Treatment (2001) (Abstract 44).
   Google Scholar
• Sulkowski M, Thomas D, Mehta S, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy. Role of hepatitis C and B infections. Hepatology 35, 182–189 (2002).
   PubMed Web of Science ®Google Scholar
• Stern J, Robinson A, Lanes S, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J. Acquir. Immune Defic. Syndr. 34, S21—S33 (2003).
   PubMed Web of Science ®Google Scholar